A Paradigm Shift in Pharmaceutical Testing

The pharmaceutical industry is undergoing a critically importent conversion, with a growing emphasis on reducing and ultimately replacing animal testing. This shift is driven by ethical concerns, regulatory changes, and the emergence of innovative technologies that offer more accurate and humane alternatives. Both Europe and the US Food and Drug Administration (FDA),a key influencer of global regulations,are signaling a move away from customary animal models,paving the way for methods like organoids and artificial intelligence (AI) to take center stage.

Bio Korea 2025 Highlights the Path Forward

The ‘Bio Korea 2025-Innovation Bio Technology’ session, recently held in Seoul, served as a platform to explore these next-generation alternatives.The event, themed “Animal Replacement Test and our Choice to Preoccupy the Future Bio Market,” showcased the potential of various technologies to revolutionize drug development.

The Ethical Imperative and Regulatory Evolution

For decades, animal testing has been a standard practice for evaluating the toxicity of new drugs before human trials. While intended to safeguard human health,this approach results in the sacrifice of over 500 million animals annually,raising significant ethical questions. The FDA’s recent policy changes mark a turning point. In 2022, the agency began accepting data beyond traditional animal studies for new drug approvals. more substantially, the FDA announced plans last month to phase out animal testing altogether, signaling a strong endorsement for alternative experimental methods.

organoids and AI: Leading the Charge

Speakers at Bio Korea 2025 emphasized the potential and competitiveness of various animal testing alternatives, with organoids and AI emerging as frontrunners. The FDA’s explicit recognition of these two fields as major alternatives has further fueled their development and adoption.

Curibio: Pioneering 3D cell-Based Solutions

Global bioventure Curibio, founded by Johns Hopkins Medical School biotechnology professor Kim Deok-ho, is at the forefront of this revolution. The company specializes in providing preclinical data using proprietary 3D cell culture plates. By developing cell models for the heart, skeletal muscles, and neuromuscular junctions, and integrating them with AI machine learning, Curibio has significantly accelerated the analysis process. With funding from the US FDA, Curibio is actively developing in vitro models to replace animal testing.

The technology will not yet replace animal research,but it is possible to present a solution in the previous stage.
Nicholas Kai, CEO of Curibio

Curibio reports that its technology has reduced the number of animals required for testing and shortened the analysis time from nine months to just 20 days, resulting in significant cost savings.

We believe that the company’s platform can be selected by using 3D cells by using 3D cells in its own experiments with global pharmaceutical companies.
nicholas Kai, CEO of Curibio

Organoid science: Versatility in Organoid Technology

Organoid Science, a KOSDAQ-listed bio venture, is leveraging the versatility of organoid technology to drive innovation. The company’s core business revolves around organoid-based research and new material evaluation solutions.

Addressing Refractory Diseases with Organoids

Organoid Science is pioneering a novel approach to treating diseases caused by viruses and bacteria, which often leave lasting damage even after the initial cause is addressed. Their lead drug candidate, Atom-Mr.,targets refractory long ulcers by directly regenerating damaged tissue.This mechanism differs from existing regenerative drugs that primarily focus on inflammation or removal of the cause. Atom-Mr. is currently undergoing clinical trials in Korea, with initial results expected this month.

Odyssey: A New Material evaluation Solution

The company’s ‘Odyssey’ platform offers a comprehensive solution for evaluating new materials, replacing animal experiments while ensuring data reliability. Odyssey provides organoid models for various tissues and organs, including tumors, intestines, skin, brain, liver, and kidneys.The tumor sector, launched in 2022, has already seen significant adoption, with comparative clinical trials demonstrating over 80% consensus with pancreatic cancer patient data. Development of a heart model, a more complex undertaking, is nearing completion, with service launch expected by the end of the year.

The Path to Commercialization

In the case of effective evaluation,I think that it will be possible to commercialize it in five years as it has already passed the request for clinical trial planning (IND).
Lee Bo-eun, Senior Manager of organoid Science

organoid Science is also developing advanced skin organoids that surpass the capabilities of existing artificial skin models used in cosmetics testing. These organoids are being utilized to evaluate hair loss prevention and hair promotion agents for companies like Cosmax, demonstrating the broad applicability of the technology.

The future is Alternative

The advancements showcased at Bio Korea 2025 and the regulatory shifts in the US and Europe point towards a future where animal testing is significantly reduced, if not entirely replaced, by more ethical and effective alternatives. Organoids, AI, and other innovative technologies are poised to revolutionize drug development, offering hope for both human health and animal welfare. The transition is underway, and the momentum is building.